[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6670590A2 - Forma de dosificación reistente a alteración que comprende un polímero aniónico - Google Patents

Forma de dosificación reistente a alteración que comprende un polímero aniónico

Info

Publication number
CO6670590A2
CO6670590A2 CO13028467A CO13028467A CO6670590A2 CO 6670590 A2 CO6670590 A2 CO 6670590A2 CO 13028467 A CO13028467 A CO 13028467A CO 13028467 A CO13028467 A CO 13028467A CO 6670590 A2 CO6670590 A2 CO 6670590A2
Authority
CO
Colombia
Prior art keywords
dosage form
polyalkylene oxide
altered
weight
anionic polymer
Prior art date
Application number
CO13028467A
Other languages
English (en)
Inventor
Lutz Barnscheid
Sebastian Schwier
Johannes Bartholomaus
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6670590(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO6670590A2 publication Critical patent/CO6670590A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una forma de dosificación farmacéutica que muestra una resistencia a rompimiento de al menos 500 N, dichaforma de dosificación conteniendo un ingrediente farmacológicamente activo (A); un polímero fisiológicamente aceptable (B) que se obtiene por polimerización de una composición de monómero comprendiendo un monómero etilénicamente no saturado que lleva un grupo funcional aniónico, en forma protonada o una sal fisiológicamente aceptable del mismo; un óxido de polialquileno (C) que tiene un peso molecular promedio ponderal de al menos 200,000 g/mol, en donde el contenido del óxido de polialquileno (C) es al menos 20% en peso, en base al peso total de la forma de dosificación; en donde el ingrediente farmacológicamente activo (A) está presente en una matriz de liberación controlada comprendiendo el polímero (B) y el óxido de polialquileno (C).
CO13028467A 2010-09-02 2013-02-12 Forma de dosificación reistente a alteración que comprende un polímero aniónico CO6670590A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10009125 2010-09-02

Publications (1)

Publication Number Publication Date
CO6670590A2 true CO6670590A2 (es) 2013-05-15

Family

ID=43719420

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13028467A CO6670590A2 (es) 2010-09-02 2013-02-12 Forma de dosificación reistente a alteración que comprende un polímero aniónico

Country Status (22)

Country Link
US (1) US9636303B2 (es)
EP (1) EP2611425B1 (es)
JP (1) JP5933553B2 (es)
KR (1) KR20130137627A (es)
CN (1) CN103179954A (es)
AR (1) AR082862A1 (es)
AU (1) AU2011297892B2 (es)
BR (1) BR112013005234A2 (es)
CA (1) CA2808541C (es)
CL (1) CL2013000424A1 (es)
CO (1) CO6670590A2 (es)
EC (1) ECSP13012472A (es)
ES (1) ES2487244T3 (es)
HK (1) HK1184390A1 (es)
MX (1) MX2013002293A (es)
NZ (1) NZ608865A (es)
PE (1) PE20131126A1 (es)
PL (1) PL2611425T3 (es)
RU (1) RU2607499C2 (es)
TW (1) TWI516286B (es)
WO (1) WO2012028318A1 (es)
ZA (1) ZA201301181B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
EP2531176B1 (en) * 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
CN104066426A (zh) * 2011-11-17 2014-09-24 格吕伦塔尔有限公司 包含药理学活性成分、阿片样物质拮抗剂和/或厌恶剂、聚环氧烷和阴离子聚合物的抗损坏口服药物剂型
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2916973A1 (en) * 2013-07-03 2015-01-08 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
ES2774304T3 (es) * 2013-08-12 2020-07-20 Pharmaceutical Manufacturing Res Services Inc Píldora extruida disuasoria de abuso, de liberación inmediata
US20160199369A1 (en) * 2013-08-12 2016-07-14 Pharmaceutical Manufacturing Research Services, Inc. Extruded Immediate Release Abuse Deterrent Pill
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
BR112017022846A2 (pt) 2015-04-24 2018-07-17 Gruenenthal Gmbh combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
US20160310486A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016170094A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2019032975A1 (en) * 2017-08-10 2019-02-14 Mec Device Pharma International Llc ANTI-ABUSE MEDICINAL FORMULATIONS
CA3112369A1 (en) * 2018-09-10 2020-03-19 Argenta Innovation Limited Controlled release formulations in delivery devices
CA3112030A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (504)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA722109A (en) 1965-11-23 W. Mock Henry Extrusion of ethylene oxide polymers
US2524855A (en) 1950-10-10 Process for the manufacture of
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US2987445A (en) 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3370035A (en) 1961-06-23 1968-02-20 Takeda Chemical Industries Ltd Stabilization of polyalkylene oxide
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
GB1147210A (en) 1965-06-30 1969-04-02 Eastman Kodak Co Improvements in or relating to vitamins
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3806603A (en) 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
DE2210071A1 (de) 1971-03-09 1972-09-14 PPG Industries Inc., Pittsburgh, Pa. (V.StA.) Verfahren zum Auftragen und Härten einer Vielzahl von Überzügen
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3966747A (en) 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US4014965A (en) 1972-11-24 1977-03-29 The Dow Chemical Company Process for scrapless forming of plastic articles
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
JPS603286B2 (ja) 1977-03-03 1985-01-26 日本化薬株式会社 定速溶出性製剤
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
DE2822324C3 (de) 1978-05-22 1981-02-26 Basf Ag, 6700 Ludwigshafen Herstellung von Vitamin-E-Trockenpulver
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
US4200704A (en) 1978-09-28 1980-04-29 Union Carbide Corporation Controlled degradation of poly(ethylene oxide)
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
US4258027A (en) 1979-03-26 1981-03-24 Mead Johnson & Company Multi-fractionable tablet structure
US4215104A (en) 1979-03-26 1980-07-29 Mead Johnson & Company Multi-fractionable tablet structure
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56169622A (en) 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4473640A (en) 1982-06-03 1984-09-25 Combie Joan D Detection of morphine and its analogues using enzymatic hydrolysis
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4427778A (en) 1982-06-29 1984-01-24 Biochem Technology, Inc. Enzymatic preparation of particulate cellulose for tablet making
US4485211A (en) 1982-09-15 1984-11-27 The B. F. Goodrich Company Poly(glycidyl ether)block copolymers and process for their preparation
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
ZA864681B (en) 1985-06-24 1987-02-25 Ici Australia Ltd Ingestible capsules
EP0328775B1 (en) 1985-06-28 1993-10-20 Carrington Laboratories, Inc. Processes for preparation of aloe products, products produced thereby and compositions thereof
US4992279A (en) 1985-07-03 1991-02-12 Kraft General Foods, Inc. Sweetness inhibitor
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
DE3689650T2 (de) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US4711894A (en) 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
US5198226A (en) 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
EP0239973A3 (en) 1986-03-31 1989-11-08 Union Carbide Corporation Catalyst and process for alkylene oxide polymerization
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE34990E (en) 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CA1335748C (en) 1986-09-25 1995-05-30 Jeffrey Lawrence Finnan Crosslinked gelatins
US5227157A (en) 1986-10-14 1993-07-13 Board Of Regents, The University Of Texas System Delivery of therapeutic agents
EP0277289B8 (en) 1986-11-10 2003-05-21 Biopure Corporation Extra pure semi-synthetic blood substitute
US4892889A (en) 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
JPH0831303B2 (ja) 1986-12-01 1996-03-27 オムロン株式会社 チツプ型ヒユ−ズ
DE3868077D1 (de) 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5051261A (en) 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
WO1989005624A1 (en) 1987-12-17 1989-06-29 The Upjohn Company Tri-scored drug tablet
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0249719A (ja) 1988-08-11 1990-02-20 Dai Ichi Kogyo Seiyaku Co Ltd 易水分散・可溶性能を有する油溶性ビタミン粉末
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4957668A (en) 1988-12-07 1990-09-18 General Motors Corporation Ultrasonic compacting and bonding particles
US5190760A (en) 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
EP0449775A3 (en) 1990-03-29 1992-09-02 Ciba-Geigy Ag Polyether-polyester block copolymers and their use as dispersing agents
SU1759445A1 (ru) 1990-06-15 1992-09-07 Ленинградский Технологический Институт Им.Ленсовета Способ получени капсулированных гидрофобных веществ
FR2664851B1 (fr) 1990-07-20 1992-10-16 Oreal Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede.
EP0477135A1 (en) 1990-09-07 1992-03-25 Warner-Lambert Company Chewable spheroidal coated microcapsules and methods for preparing same
US5126151A (en) 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JPH051737A (ja) 1991-06-20 1993-01-08 Toyota Motor Corp 回転式緩衝装置
JP3073054B2 (ja) 1991-07-11 2000-08-07 住友精化株式会社 アルキレンオキシド重合体の製造方法
DK0662320T3 (da) 1991-08-30 2001-09-24 Showa Pharm Chem Ind Tør gelsammensætning
EP0664118B1 (en) 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
WO1993006723A1 (en) 1991-10-04 1993-04-15 Olin Corporation Fungicide tablet
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
EP0615438B1 (en) 1991-12-05 1996-07-24 Mallinckrodt Veterinary, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
DE59302200D1 (de) 1992-05-22 1996-05-15 Goedecke Ag Verfahren zur herstellung retardierter arzneimittelzubereitungen
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
DE4229085C2 (de) 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
NZ255579A (en) 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
AU683044B2 (en) 1992-12-23 1997-10-30 Saitec S.R.L. Process for preparing controlled release pharmaceutical forms and the forms thus obtained
GB2273874A (en) 1992-12-31 1994-07-06 Pertti Olavi Toermaelae Preparation of pharmaceuticals in a polymer matrix
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE4309528C2 (de) 1993-03-24 1998-05-20 Doxa Gmbh Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
ATE212224T1 (de) 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
AU1266895A (en) 1993-12-20 1995-07-10 Procter & Gamble Company, The Process for making laxatives containing dioctyl sulfosuccinate
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
PT744941E (pt) 1994-02-16 2003-10-31 Abbott Lab Processo para preparar formulacoes farmaceuticas de particulas finas
SE9503924D0 (sv) 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SI9520049A (en) 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
IT1274879B (it) 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
JP3285452B2 (ja) 1994-08-11 2002-05-27 サンスター株式会社 歯磨組成物
US5837790A (en) 1994-10-24 1998-11-17 Amcol International Corporation Precipitation polymerization process for producing an oil adsorbent polymer capable of entrapping solid particles and liquids and the product thereof
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5900425A (en) 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19522899C1 (de) 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Verfahren zum kontinuierlichen Ersintern eines Granulats
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
DE19547766A1 (de) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
DE69709646T2 (de) 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
AU713277B2 (en) 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US20020114838A1 (en) 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
ATE427124T1 (de) 1996-06-26 2009-04-15 Univ Texas Heiss-geschmolzene extrudierbare pharmazeutische formulierung
ES2322405T3 (es) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
NL1003684C2 (nl) 1996-07-25 1998-01-28 Weterings B V H Inrichting voor het afgeven van een vloeistof.
DE19630236A1 (de) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle
BE1010353A5 (fr) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus.
ES2229591T3 (es) 1996-11-05 2005-04-16 Novamont S.P.A. Composiciones polimericas biodegradables que comprenden almidon y un polimero termoplastico.
US5991799A (en) 1996-12-20 1999-11-23 Liberate Technologies Information retrieval system using an internet multiplexer to focus user selection
DE19705538C1 (de) 1997-02-14 1998-08-27 Goedecke Ag Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US6139770A (en) 1997-05-16 2000-10-31 Chevron Chemical Company Llc Photoinitiators and oxygen scavenging compositions
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
AU741599B2 (en) 1997-09-10 2001-12-06 Fram Group Ip Llc Injection molding of structural zirconia-based materials by an aqueous process
US6009390A (en) 1997-09-11 1999-12-28 Lucent Technologies Inc. Technique for selective use of Gaussian kernels and mixture component weights of tied-mixture hidden Markov models for speech recognition
WO1999027891A2 (de) 1997-11-28 1999-06-10 Knoll Aktiengesellschaft Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
KR20010032718A (ko) 1997-12-03 2001-04-25 빌프리더 하이더 폴리에테르 에스테르 아미드
DE19753534A1 (de) 1997-12-03 1999-06-10 Bayer Ag Schnell kristallisierende, biologisch abbaubare Polyesteramide
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417490B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
DE19800689C1 (de) 1998-01-10 1999-07-15 Deloro Stellite Gmbh Formkörper aus einem verschleißfesten Werkstoff
DE19800698A1 (de) 1998-01-10 1999-07-15 Bayer Ag Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten
JP3753254B2 (ja) 1998-03-05 2006-03-08 三井化学株式会社 ポリ乳酸樹脂組成物及びそれからなるフィルム
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6110500A (en) 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
EP1070346A1 (en) 1998-04-02 2001-01-24 Applied Materials, Inc. Method for etching low k dielectrics
ES2221370T3 (es) 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
US5962488A (en) 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
DE19822979A1 (de) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung
US6333087B1 (en) 1998-08-27 2001-12-25 Chevron Chemical Company Llc Oxygen scavenging packaging
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
US6268177B1 (en) 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase
WO2000023073A1 (en) 1998-10-20 2000-04-27 Korea Institute Of Science And Technology Bioflavonoids as plasma high density lipoprotein level increasing agent
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
ES2141688B1 (es) 1998-11-06 2001-02-01 Vita Invest Sa Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19856147A1 (de) 1998-12-04 2000-06-08 Knoll Ag Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
WO2000040205A2 (en) 1999-01-05 2000-07-13 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
KR20010034730A (ko) 1999-02-04 2001-04-25 아키라 이가키 동맥경화 예방물질, 면역활성화물질, 이들 물질을섭식하는 포유동물, 및 그의 알
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
CA2379987A1 (en) 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
CA2388560A1 (en) 1999-08-31 2001-03-08 Grunenthal Gmbh Sustained-release form of administration containing tramadol saccharinate
DE19940740A1 (de) 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
DE19960494A1 (de) 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
PT2277521E (pt) 2000-02-08 2015-07-01 Euro Celtique Sa Formulações orais de agonistas de opióides resistentes a adulteração
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6572887B2 (en) 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
BR0111125A (pt) 2000-05-23 2004-12-28 Cenes Pharmaceuticals Inc Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10036400A1 (de) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh Weiße, biaxial orientierte Polyesterfolie
WO2002026262A2 (en) 2000-09-25 2002-04-04 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
JP2004509634A (ja) 2000-09-27 2004-04-02 ダニスコ　エイ／エス 抗菌剤
WO2002026928A1 (en) 2000-09-28 2002-04-04 The Dow Chemical Company Polymer composite structures useful for controlled release systems
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU2002226098A1 (en) 2000-10-30 2002-05-15 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP2002265592A (ja) 2001-03-07 2002-09-18 Sumitomo Seika Chem Co Ltd アルキレンオキシド重合体の製造方法
WO2002071860A1 (en) 2001-03-13 2002-09-19 L.A. Dreyfus Co. Gum base and gum manufacturing using particulated gum base ingredients
JP3967554B2 (ja) 2001-03-15 2007-08-29 株式会社ポッカコーポレーション フラボノイド化合物及びその製造方法
US20020132395A1 (en) 2001-03-16 2002-09-19 International Business Machines Corporation Body contact in SOI devices by electrically weakening the oxide under the body
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
IL158620A0 (en) 2001-05-01 2004-05-12 Union Carbide Chem Plastic Poly (alkylene oxides) having reduced amounts of formic compounds
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030008409A1 (en) 2001-07-03 2003-01-09 Spearman Steven R. Method and apparatus for determining sunlight exposure
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
ATE376832T1 (de) 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
JP2003020517A (ja) 2001-07-10 2003-01-24 Calp Corp 複合繊維用樹脂組成物
DE60230632D1 (de) 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US6883976B2 (en) 2001-07-30 2005-04-26 Seikoh Giken Co., Ltd. Optical fiber ferrule assembly and optical module and optical connector using the same
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
JP2005501067A (ja) 2001-08-06 2005-01-13 ユーロ−セルティーク，エス．エイ． オピオイドの乱用を防ぐための組成物および方法
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP3474870B2 (ja) 2001-08-08 2003-12-08 菱計装株式会社 昇降機
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030059467A1 (en) 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
ATE381924T1 (de) 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
AU2002342755A1 (en) 2001-09-26 2003-04-14 Klaus-Jurgen Steffens Method and device for producing granulates that comprise at least one pharmaceutical active substance
EP1429730A4 (en) 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
EP1463489A1 (en) 2001-09-28 2004-10-06 McNEIL-PPC, INC. Composite dosage forms
MXPA04003306A (es) 2001-10-09 2004-07-23 Procter & Gamble Composiciones acuosas para tratar superficies.
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
JP2003125706A (ja) 2001-10-23 2003-05-07 Lion Corp 口中清涼製剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP4551089B2 (ja) 2001-10-29 2010-09-22 マサチューセッツ インスティテュート オブ テクノロジー 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム
EP1450824A4 (en) 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
WO2003049689A2 (en) 2001-12-06 2003-06-19 Nutraceutix, Inc. Isoflavone composition for oral delivery
FR2833838B1 (fr) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu
AUPS044502A0 (en) 2002-02-11 2002-03-07 Commonwealth Scientific And Industrial Research Organisation Novel catalysts and processes for their preparation
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
DE10217232B4 (de) 2002-04-18 2004-08-19 Ticona Gmbh Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
CA2483655A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
EP1515674A4 (en) 2002-05-13 2008-04-09 Endo Pharmaceuticals Inc AGAINST MISUSE PROTECTED SOLID OPIOID DOSAGE FORM
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US20050175690A1 (en) 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
CA2491572C (en) 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040011806A1 (en) 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
AR040680A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US7388068B2 (en) 2002-08-21 2008-06-17 Clariant Produkte (Deutschland) Gmbh Copolymers made of alkylene oxides and glycidyl ethers and use thereof as polymerizable emulsifiers
US20060099250A1 (en) 2002-08-21 2006-05-11 Wei Tian Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets
US20040052844A1 (en) 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
KR20050084559A (ko) 2002-09-17 2005-08-26 와이어쓰 경구 제형
AU2003275145B2 (en) 2002-09-20 2008-07-24 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
AU2003271024A1 (en) 2002-09-21 2004-04-08 Jin Wang Sustained release compound of acetamidophenol and tramadol
CA2499994C (en) 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
DE10250088A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
JP2006507277A (ja) 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド ２４時間有効な持続放出トラマドール製剤
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1603597B1 (en) 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
JP4989217B2 (ja) 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
WO2004093819A2 (en) 2003-04-21 2004-11-04 Euro-Celtique, S.A. Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
PE20081297A1 (es) 2003-04-30 2008-09-17 Purdue Pharma Lp Forma de dosificacion transdermica resistente a la manipulacion
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CN1473562A (zh) * 2003-06-27 2004-02-11 辉 刘 儿用口腔速溶、速崩冻干片及其制备方法
US20050015730A1 (en) 2003-07-14 2005-01-20 Srimanth Gunturi Systems, methods and computer program products for identifying tab order sequence of graphically represented elements
RU2339365C2 (ru) 2003-08-06 2008-11-27 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PE20050728A1 (es) 2003-08-06 2005-11-10 Gruenenthal Chemie Forma de dosificacion a prueba de abuso
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CL2004002016A1 (es) 2003-08-06 2005-05-20 Gruenenthal Chemie Forma de dosificacion termoformada a prueba de abuso que contiene (a) uno o mas principios activos susceptibles de abuso, (b) opcionalmente sustancias auxiliares, (c) al menos un polimero sintetico o natural definido y (d) opcionalmente al menos una
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20050063214A1 (en) 2003-09-22 2005-03-24 Daisaburo Takashima Semiconductor integrated circuit device
DK1663229T3 (da) 2003-09-25 2010-08-09 Euro Celtique Sa Farmaceutiske kombinationer af hydrocodon og naltrexon
JP2007507513A (ja) 2003-09-30 2007-03-29 アルザ・コーポレーション 上昇傾向のレリース特性を生ずる浸透圧駆動活性剤供給装置
US20060172006A1 (en) 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060009478A1 (en) 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
BRPI0415639A (pt) 2003-10-29 2006-12-12 Alza Corp formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1689368B1 (en) 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
CA2548834C (en) 2003-12-09 2009-08-11 Euro-Celtique S.A. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2005060942A1 (en) 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403100D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Particulates
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
DE102004019916A1 (de) 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2005102286A1 (de) 2004-04-22 2005-11-03 Grünenthal GmbH Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
WO2005105036A1 (en) 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
TWI428271B (zh) 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
PL1612203T3 (pl) 2004-06-28 2007-12-31 Gruenenthal Gmbh Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
ITMI20041317A1 (it) 2004-06-30 2004-09-30 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PL1765303T5 (pl) 2004-07-01 2023-05-22 Grünenthal GmbH Tabletka doustna zabezpieczona przed nadużywaniem
AR049839A1 (es) 2004-07-01 2006-09-06 Gruenenthal Gmbh Procedimiento para la produccion deuna forma farmaceutica solida, protegida frente al abuso
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
KR20060007225A (ko) 2004-07-19 2006-01-24 삼성전자주식회사 촬상소자 구동제어와 메모리 읽기제어를 이용한 손떨림보정방법 및 이를 적용한 촬영장치
DE602005007237D1 (de) 2004-07-27 2008-07-10 Unilever Nv Haarpflegezusammensetzungen
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20060068009A1 (en) 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
CN101132772B (zh) 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7292616B2 (en) 2005-02-09 2007-11-06 Ultratech, Inc. CO2 laser stabilization systems and methods
US20060194759A1 (en) 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
PT1861405E (pt) 2005-03-04 2009-07-27 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
CA2603649C (en) 2005-04-08 2014-10-14 Ozpharma Pty Ltd Buccal delivery system
KR20080007357A (ko) 2005-05-10 2008-01-18 노파르티스 아게 압축성이 열등한 치료학적 화합물을 갖는 조성물을제조하는 압출방법
AU2006254554B2 (en) 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
BRPI0612802A2 (pt) 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1909760A1 (en) 2005-08-03 2008-04-16 Eastman Chemical Company Tocopheryl polyethylene glycol succinate powder and process for preparing same
US8133871B2 (en) 2005-10-14 2012-03-13 The Kitasato Institute Dihydropseudoerythromycin derivatives
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
FR2892937B1 (fr) 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
CA2637755A1 (en) 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20100226855A1 (en) 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
ATE448231T1 (de) 2006-03-02 2009-11-15 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on- produkten mit geringen konzentrationen von alpha-,beta-ungesättigten ketonverbindungen
US20070224637A1 (en) 2006-03-24 2007-09-27 Mcauliffe Joseph C Oxidative protection of lipid layer biosensors
CN101489756B (zh) 2006-03-24 2013-08-07 奥克思利尤姆国际控股公司 热熔挤出层压材料的制备方法
EP2010156B1 (en) 2006-03-24 2016-11-16 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
CN101091721A (zh) 2006-06-22 2007-12-26 孙明 阿胶新剂型的制备方法
JP4029109B1 (ja) 2006-07-18 2008-01-09 タマ生化学株式会社 ビタミンｅとプロリンの複合体粉末及びその製造方法
AU2007275033A1 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR101400824B1 (ko) 2006-09-25 2014-05-29 후지필름 가부시키가이샤 레지스트 조성물, 이 레지스트 조성물에 사용되는 수지, 이수지의 합성에 사용되는 화합물, 및 상기 레지스트조성물을 사용한 패턴형성방법
US8187636B2 (en) 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
GB0624880D0 (en) 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
NZ577560A (en) 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20080181932A1 (en) 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
CN100579525C (zh) 2007-02-02 2010-01-13 东南大学 盐酸尼卡地平缓释制剂及其制备方法
CN101057849A (zh) 2007-02-27 2007-10-24 齐齐哈尔医学院 含有盐酸二甲双胍和格列吡嗪的缓释制剂及其制备方法
US10888521B2 (en) 2007-03-02 2021-01-12 Farnam Companies, Inc. Sustained release compositions using wax-like materials
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1980245A1 (en) 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
WO2008142627A2 (en) 2007-05-17 2008-11-27 Ranbaxy Laboratories Limited Multilayered modified release formulation comprising amoxicillin and clavulanate
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
DE102007030308A1 (de) 2007-06-29 2009-01-02 Printed Systems Gmbh Verfahren zum Herstellen einer Speicherstruktur
CA2690956C (en) 2007-07-01 2017-01-03 Joseph Peter Habboushe Combination tablet with chewable outer layer
WO2009014534A1 (en) 2007-07-20 2009-01-29 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
EP2200591A2 (en) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
CA2699142C (en) 2007-09-13 2016-05-17 Cima Labs Inc. Abuse resistant drug formulation
EP2211760A4 (en) 2007-10-17 2013-09-18 Axxia Pharmaceuticals Llc POLYMER DRUG DELIVERY SYSTEMS AND METHODS OF EXTRUSION OF THERMOPLASTIC COMPOUNDS TO PRODUCE THESE SYSTEMS
SI2596784T1 (sl) 2007-11-23 2017-04-26 Gruenenthal Gmbh Sestavki tapentadola
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
CA2707282A1 (en) 2007-12-12 2009-06-18 Basf Se Salts of active ingredients with polymeric counterions
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
KR100970665B1 (ko) 2008-02-04 2010-07-15 삼일제약주식회사 알푸조신 또는 그의 염을 함유하는 서방성 정제
BRPI0909030A2 (pt) 2008-03-05 2018-03-13 Panacea Biotec Ltd composições farmacêuticas de liberação modificada compreendendo micofenolato e processos para as mesmas.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
RU2491918C2 (ru) 2008-07-03 2013-09-10 Новартис Аг Способ грануляции из расплава
CN102271661A (zh) * 2008-08-20 2011-12-07 德克萨斯州立大学董事会 缓释多颗粒的热熔挤出
US20100099696A1 (en) 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
US20100104638A1 (en) 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
CN102271663A (zh) 2008-11-14 2011-12-07 波托拉医药品公司 控制释放在低pH下水溶性差的可电离活性药物的固体组合物及其用法
PL2379111T3 (pl) 2008-12-12 2013-08-30 Paladin Labs Inc Preparaty leków narkotycznych o obniżonym potencjale uzależniającym
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2750400A1 (en) 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
AU2010211376B2 (en) 2009-02-06 2013-08-22 Egalet Ltd. Pharmaceutical compositions resistant to abuse
PL2408436T3 (pl) 2009-03-18 2017-08-31 Evonik Röhm Gmbh Kompozycja farmaceutyczna o kontrolowanym uwalnianiu z odpornością na wpływ etanolu, wykorzystująca powłokę zawierającą neutralne polimery winylowe i zaróbki
EP2246063A1 (en) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
WO2011008298A2 (en) 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
EP2531176B1 (en) 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP3064199B1 (en) 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
RU2013114411A (ru) 2010-09-02 2014-10-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
JP5638151B2 (ja) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
JP2014505736A (ja) 2011-02-17 2014-03-06 キューアールエックスファーマ リミテッド 固体投薬形態の乱用を防止するための技術
EP3685827A1 (en) 2011-03-04 2020-07-29 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
JP6042880B2 (ja) 2011-06-01 2016-12-14 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 放出を制御された固形剤形
WO2013003845A1 (en) 2011-06-30 2013-01-03 Neos Therapeutics, Lp Abuse resistant drug forms
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
FR2979242A1 (fr) 2011-08-29 2013-03-01 Sanofi Sa Comprime contre l'usage abusif, a base de paracetamol et d'oxycodone
US20130090349A1 (en) 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
CN104066426A (zh) 2011-11-17 2014-09-24 格吕伦塔尔有限公司 包含药理学活性成分、阿片样物质拮抗剂和/或厌恶剂、聚环氧烷和阴离子聚合物的抗损坏口服药物剂型
JP6144274B2 (ja) 2011-12-09 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ ポリ（イプシロン−カプロラクトン）およびポリエチレンオキシドを含む医薬剤形
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PE20142320A1 (es) 2012-03-02 2015-01-16 Rhodes Pharmaceuticals Lp Formulaciones de liberacion inmediata resistentes a la manipulacion
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
NO2846835T3 (es) 2012-05-11 2018-02-03
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2906202A4 (en) 2012-10-15 2016-04-27 Isa Odidi DRUG FORMULATIONS FOR ORAL ADMINISTRATION
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2817728A1 (en) 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US10744131B2 (en) 2013-12-31 2020-08-18 Kashiv Biosciences, Llc Abuse-resistant drug formulations

Also Published As

Publication number Publication date
CN103179954A (zh) 2013-06-26
MX2013002293A (es) 2013-05-09
US20120065220A1 (en) 2012-03-15
ECSP13012472A (es) 2013-04-30
CA2808541C (en) 2019-01-08
ZA201301181B (en) 2013-10-30
WO2012028318A1 (en) 2012-03-08
PL2611425T3 (pl) 2014-09-30
EP2611425B1 (en) 2014-07-02
KR20130137627A (ko) 2013-12-17
US9636303B2 (en) 2017-05-02
CL2013000424A1 (es) 2013-04-12
AU2011297892B2 (en) 2014-05-29
JP5933553B2 (ja) 2016-06-15
HK1184390A1 (en) 2014-01-24
CA2808541A1 (en) 2012-03-08
AR082862A1 (es) 2013-01-16
TWI516286B (zh) 2016-01-11
AU2011297892A1 (en) 2013-04-18
ES2487244T3 (es) 2014-08-20
RU2607499C2 (ru) 2017-01-10
BR112013005234A2 (pt) 2016-05-03
NZ608865A (en) 2015-03-27
RU2013114406A (ru) 2014-10-10
EP2611425A1 (en) 2013-07-10
TW201217002A (en) 2012-05-01
JP2013536810A (ja) 2013-09-26
PE20131126A1 (es) 2013-10-21

Similar Documents

Publication Publication Date Title
CO6670590A2 (es) Forma de dosificación reistente a alteración que comprende un polímero aniónico
CO6670546A2 (es) Forma de dosificación reistente a manipulación que comprende una sal inorgánica
CO6670598A2 (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
MX2012000644A (es) Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion.
MX2014005820A (es) Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico.
CY1120783T1 (el) Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας
MX2014013095A (es) Forma de dosificacion farmaceutica termoconformada, resistente al uso indebido, que contiene zinc.
BR112014019988A8 (pt) Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
AR096439A1 (es) Forma de dosificación resistente al uso indebido que contiene una o más partículas
MX2010008138A (es) Forma de dosis farmaceutica.
CL2012002808A1 (es) Composición que comprende un polímero derivado de al menos dos monómeros: acrilico-x y una alquilamina, en donde el peso molecular del polimero es de entre 500 a 200.000 y, ademas, el polimero es modificado para contener un grupo funcional capaz de depurar una o mas composiciones que contienen uno o mas metales.
EA201792345A1 (ru) Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
ES2571435T3 (es) Composiciones de nanopartículas que contienen polímeros e insecticidas de diamida de ácido antranílico para recubrimiento de propágulos
EA201070175A1 (ru) Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид
ECSP14000928A (es) Forma de dósis farmacéutica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico